Antengene To Present One Oral and Four Abstracts at ASCO 2024
/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated...
Source: prnewswire.com
Bayesian Optimal Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bayesian Optimal Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bayesian Optimal Interval Today - Breaking & Trending Today
CytomX Therapeutics Reports 2023 Financial Results and
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase...
Source: globenewswire.com
Carina Biotech Doses First Patient in Phase 1/2a Clinical
First patient dosed in Australia where 3 clinical trial sites have been activated.The trial will enrol advanced colorectal cancer patients whose cancer...
Source: globenewswire.com
Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors
Lirafugratinib demonstrated clinical activity in multiple subsets of patients with FGFR2-altered solid tumors, including those with FGFR2-altered hormone receptor–positive, HER2-negative breast cancer.
Source: onclive.com
Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS
The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents.
Source: onclive.com